Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia

Lancet

Volumn 359, Issue 9311, 2002, Pages 1033-1034

  Krajinovic, M ^a,b   Costea, I ^a   Chiasson, S ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; METHOTREXATE; THYMIDYLATE SYNTHASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; ASSOCIATION; BLOOD; BONE MARROW; CHEEK MUCOSA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; EPITHELIUM CELL; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REMISSION; RISK; TANDEM REPEAT; TREATMENT OUTCOME;

EID: 0037161062     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08065-0     Document Type: Article

References (5)

1. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues
2. mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method
3. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase
4. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers
5. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil